Objective To investigate the clinical prognostic value of the prognostic nutritional index (PNI) in patients with renal cell carcinoma (RCC) undergoing partial nephrectomy.Methods A retrospective analysis was conducted on the clinical data of RCC patients who underwent partial nephrectomy at our hospital during 2020 and 2024.The optimal cutoff value of PNI was determined based on the maximum Youden index from the receiver operating characteristic (ROC) curve.The clinicopathological characteristics, overall survival (OS), and progression-free survival (PFS) between patients with different PNI levels were compared.Cox regression analysis was used to explore the independent prognostic factors for RCC patients. Results Based on the ROC curve, the optimal cutoff value corresponding to the maximum Youden index was calculated to be 46.675, at which point the sensitivity was 65.3% and the specificity was 62.2%.Of the 815 patients included in the study, 293 (36.0%) patients had a PNI＜46.675.Cox regression analysis confirmed that preoperative PNI, tumor diameter, ISUP classification, and ECOG score were independent risk factors for postoperative OS in patients with RCC who underwent PN (P＜0.05).In addition, preoperative PNI, tumor diameter, ISUP classification and ECOG score were independent risk factors for postoperative PFS (P＜0.05).After covariates in the multivariable Cox regression model were adjusted, patients in the low PNI group demonstrated significantly shorter overall survival (HR=2.392, P＜0.001) and significantly poorer progression-free survival (HR=2.076, P＜0.001) compared to those in the high PNI group.Conclusion Preoperative PNI has significant clinical value in evaluating the prognosis of RCC patients undergoing partial nephrectomy.An elevated preoperative PNI is associated with a better prognosis.

Objective To evaluate the efficacy and safety of biomaterial sling in the treatment of female stress urinary incontinence (SUI), so as to explore the possibility of replacing traditional synthetic materials with biomaterials in SUI surgery. Methods Clinical data of 22 SUI patients undergoing retropubic mid-urethral sling surgery in our hospital during Jan.and Dec.2023 were retrospectively collected. Perioperative parameters were analyzed, and all patients were followed up for more than one year. The quality of life was assessed using the incontinence impact questionnaire-short form-7 (IIQSF-7), numerical rating scale (NRS), and urogenital distress inventory-short form-6 (UDI-6). Results All 22 operations were successfully completed. The follow-up was 13-25 (mean 15.2±4.6) months, operation time (47.0±11.1) minutes, hospital stay (0.8± 0.2) days, and pain duration (6.1±4.9) days. One year after surgery, all patients'NRS, IIQSF-7 and UDI-6 scores were significantly reduced (P<0.001). One week after surgery, all patients were improved. No sling exposure or urinary tract infection was found during the follow-up. Conclusion Biomaterial sling is an effective and relatively safe method for the treatment of female SUI, demonstrating satisfactory short-term outcomes. However, the long-term effects still need further research.

Objective To investigate the expression and clinical significance of microRNA-224 and microRNA-378e in colorectal cancer tissues and normal mucosa adjacent to tumor lesions. Methods The gene chip technology was used to detect the different expression of miRNA in colorectal carcinoma tissues and adjacent normal tissues, which was then confirmed by real-time PCR. The relationship between the pathology and clinical data was analyzed. Results The expres-sion level of miR-224 was significantly up-regulated in tumor tissue, while miR-378e was down-regulated in tumor tissue, which was confirmed by real-time PCR. The expression of miR-224 was strongly associated with histological types, while miR-378e was strongly associated with the infiltration depth of colorectal cancer. Conclusion miR-224 is a potent tumor promoter, while miR-378e is a potent tumor suppressor. Both miR-224 and miR-378e can be used as potential colorectal cancer molecular markers.